Moleculin CEO, Walter Klemp highlights Annamycin differentiation in the current AML treatment landscape and potential opportunity

FRENCHTOWN, NJ / ACCESSWIRE / April 25, 2024 / JTC Team ("JTC"), a fully integrated corporate communications and investor relations firm, today released a Virtual Investor "What This Means" segment featuring Moleculin Biotech (NASDAQ:MBRX), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting hard-to-treat tumors and viruses.

Watch the "What This Means" video here

As part of this "What This Means" segment, Walter Klemp, Chairman and Chief Executive Officer of Moleculin, discusses highlights from the Company's recently announced positive interim data from its ongoing clinical trial evaluating Annamycin for the treatment of subjects with Acute Myeloid Leukemia (AML), how Annamycin is differentiated in the current treatment landscape, and the Moleculin investment opportunity.

The Virtual Investor "What This Means" segment featuring Moleculin Biotech is now available here. Additional videos from the "What This Means" series are available on demand at www.virtualinvestorco.com.

About JTC Team

JTC is a fully integrated corporate communications firm that is dedicated to helping you tell your story to the right audiences in order to build awareness. JTC has developed a reputation of excellence for executing robust communication strategies that deliver results. The Company partners with both public and private companies across the Life Sciences and Technology industries to help raise awareness and build stakeholder value. For more information, please visit www.jtcir.com or connect with the company on Twitter and LinkedIn.

Contact:

Jenene Thomas
JTC Team, LLC
T: +1 (833) 475-8247
jtc@jtcir.com

SOURCE: JTC Team, LLC